Shares in La Jolla Pharmaceutical Company (NASDAQ:LJPC) surged 41% today ahead of the opening bell in the US after announcing positive top line results from the phase 3 study of its treatment for hypotension.
The ATHOS-3 study of the LJPC-501 drug, or angiotensin II, showed a highly statistically significant target blood pressure response, the primary efficacy endpoint, in patients with catecholamine resistant hypotension.
Hypotension is severely low blood pressure, which can lead to a life-threatening condition called shock.
The pharmaceutical company said the study revealed a trend towards longer survival with a 22% reduction in mortality risks.
An independent data safety monitoring board recommended the study continue as planned.
La Jolla plans to publish detailed results from ATHOS-3 later this year.
“These study results support that angiotensin II, a molecule first synthesised by Dr. Irvine Page at the Cleveland Clinic, improves outcomes in distributive shock patients requiring high-dose catecholamines,” said Daniel Sessler, chair of the Department of Outcomes Research at Cleveland Clinic.
“Given the high mortality from this condition, it is important to offer physicians another potential treatment option.”
Shares jumped 41.27% to $19.87 in pre-market trade.
Story by ProactiveInvestors